Prometheus Biosciences to Participate at the Jefferies Healthcare Conference
May 26 2022 - 8:00AM
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage
biotechnology company pioneering a precision medicine approach for
the discovery, development, and commercialization of novel
therapeutic and companion diagnostic products for the treatment of
immune-mediated diseases, today announced that management will
present at the Jefferies Healthcare Conference on June 8, 2022 at
10:00 AM ET.
A live and archived webcast of the presentation
will be available via the Events & Webcasts page on the
Investor section of the Prometheus Biosciences website.
About Prometheus
Biosciences
Prometheus Biosciences, Inc. is a clinical-stage biotechnology
company pioneering a precision medicine approach for the discovery,
development, and commercialization of novel therapeutic and
companion diagnostic products for the treatment of immune-mediated
diseases. The Company’s precision medicine platform,
Prometheus360TM, combines proprietary machine learning-based
analytical approaches with one of the world’s largest
gastrointestinal bioinformatics databases to identify novel
therapeutic targets and develop therapeutic candidates to engage
those targets.
The Company’s lead candidate, PRA023, is an IgG1 humanized
monoclonal antibody (mAb) for the treatment of immune-mediated
diseases including Ulcerative colitis (UC), Crohn’s disease (CD),
and systemic sclerosis-associated interstitial lung disease
(SSc-ILD). The Company is currently conducting three Phase 2
studies of PRA023: a Phase 2 trial in UC patients, ARTEMIS-UC, a
Phase 2a trial in CD patients, APOLLO-CD, and a Phase 2 clinical
trial in SSc-ILD, ATHENA-SSc-ILD, each utilizing a genetic-based
companion diagnostic candidate designed to classify patients who
are predisposed to increased expression of TL1A and therefore
potentially more likely to respond to PRA023.
Prometheus Biosciences Contact:Noel KurdiVP
Investor Relations and Communications(646)
241-4400nkurdi@prometheusbiosciences.com
Media contact:Juniper PointAmy Conrad (858)
914-1962media@prometheusbiosciences.com
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Apr 2023 to Apr 2024